Overview

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb